Gerald Lushington is co-founder or TheraPeptics, LLC, a startup effort focused on applying artificial intelligence and bioinspiration for developing novel peptide formulations for antimicrobial, anticancer and immunotherapeutic medicines, as well as for a variety of analytical and diagnostic technologies. Dr. Lushington's other key biomedical interests include antiviral protease targeting and neuropathic mechanistic studies. His primary technical specializations are in informatics, modeling, and visualization as applied to a diverse range of chemical and biological foci. He is Editor in Chief of the journal Combinatorial Chemistry & High Throughput Screening (Bentham Scientific) and serves on editorial boards of numerous other journals.
Dr. Lushington completed his Ph.D. at the age of 26 years from the University of New Brunswick in Canada. He has over 200 publications that have been cited over 4100 times, amounting to an H-index of 35.